Peter E. Hall

1.8k total citations
38 papers, 1.1k citations indexed

About

Peter E. Hall is a scholar working on Public Health, Environmental and Occupational Health, Oncology and Surgery. According to data from OpenAlex, Peter E. Hall has authored 38 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Public Health, Environmental and Occupational Health, 9 papers in Oncology and 5 papers in Surgery. Recurrent topics in Peter E. Hall's work include Reproductive Health and Contraception (13 papers), Cancer Research and Treatments (5 papers) and Cancer Immunotherapy and Biomarkers (4 papers). Peter E. Hall is often cited by papers focused on Reproductive Health and Contraception (13 papers), Cancer Research and Treatments (5 papers) and Cancer Immunotherapy and Biomarkers (4 papers). Peter E. Hall collaborates with scholars based in United Kingdom, Switzerland and United States. Peter E. Hall's co-authors include Justin D. Lathia, Charles ffrench‐Constant, Maeve A. Caldwell, Nigel Miller, Catherine d’Arcangues, Richard Newton, Peter W. Szlosarek, A. Pretnar‐Darovec, Suporn Koetsawang and Juan Dı́az and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cochrane Database of Systematic Reviews.

In The Last Decade

Peter E. Hall

37 papers receiving 1.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Peter E. Hall United Kingdom 18 341 264 151 143 134 38 1.1k
P Cortinovis-Tourniaire France 5 358 1.0× 104 0.4× 61 0.4× 36 0.3× 97 0.7× 5 1.5k
Padmalaya Das United States 18 277 0.8× 872 3.3× 39 0.3× 77 0.5× 21 0.2× 46 1.8k
Stephen R. Braddock United States 25 302 0.9× 525 2.0× 52 0.3× 27 0.2× 17 0.1× 71 1.7k
P. J. McLaughlin United States 17 55 0.2× 283 1.1× 26 0.2× 210 1.5× 53 0.4× 27 745
David B. Flannery United States 18 197 0.6× 381 1.4× 16 0.1× 49 0.3× 16 0.1× 45 1.2k
Arabella Smith Australia 22 132 0.4× 605 2.3× 28 0.2× 21 0.1× 53 0.4× 119 1.8k
Aurora Sánchez Spain 25 178 0.5× 810 3.1× 16 0.1× 295 2.1× 106 0.8× 91 1.9k
J. Wahlström Sweden 33 119 0.3× 648 2.5× 11 0.1× 105 0.7× 24 0.2× 91 2.6k
Peter T. Rowley United States 23 70 0.2× 553 2.1× 71 0.5× 74 0.5× 17 0.1× 81 1.6k

Countries citing papers authored by Peter E. Hall

Since Specialization
Citations

This map shows the geographic impact of Peter E. Hall's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter E. Hall with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter E. Hall more than expected).

Fields of papers citing papers by Peter E. Hall

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter E. Hall. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter E. Hall. The network helps show where Peter E. Hall may publish in the future.

Co-authorship network of co-authors of Peter E. Hall

This figure shows the co-authorship network connecting the top 25 collaborators of Peter E. Hall. A scholar is included among the top collaborators of Peter E. Hall based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter E. Hall. Peter E. Hall is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Hall, Peter E. & Peter Schmid. (2022). Emerging strategies for TNBC with early clinical data: new chemoimmunotherapy strategies. Breast Cancer Research and Treatment. 193(1). 21–35. 8 indexed citations
3.
Mukherjee, Uma, et al.. (2022). Arginine Deprivation in SCLC: Mechanisms and Perspectives for Therapy. SHILAP Revista de lepidopterología. Volume 13. 53–66. 12 indexed citations
4.
Szlosarek, Peter W., Akhila Wimalasingham, Melissa Phillips, et al.. (2021). Phase 1, pharmacogenomic, dose‐expansion study of pegargiminase plus pemetrexed and cisplatin in patients with ASS1‐deficient non‐squamous non‐small cell lung cancer. Cancer Medicine. 10(19). 6642–6652. 14 indexed citations
5.
Crusz, Shanthini Mary, et al.. (2021). Providing an acute oncology service during the COVID-19 pandemic. Clinical Medicine. 21(5). e548–e551. 2 indexed citations
6.
Hall, Peter E. & Peter Schmid. (2021). Emerging drugs for the treatment of triple-negative breast cancer: a focus on phase II immunotherapy trials. Expert Opinion on Emerging Drugs. 26(2). 131–147. 8 indexed citations
7.
Hall, Peter E., Neal Ready, Amanda Johnston, et al.. (2020). Phase II Study of Arginine Deprivation Therapy With Pegargiminase in Patients With Relapsed Sensitive or Refractory Small-cell Lung Cancer. Clinical Lung Cancer. 21(6). 527–533. 24 indexed citations
8.
Powles, Thomas, Janet E. Brown, James Larkin, et al.. (2016). A randomized, double-blind phase II study evaluating cediranib versus cediranib and saracatinib in patients with relapsed metastatic clear-cell renal cancer (COSAK). Annals of Oncology. 27(5). 880–886. 16 indexed citations
9.
Hall, Peter E., James Spicer, & Sanjay Popat. (2015). Rationale for Targeting the ErbB Family of Receptors in Patients with Advanced Squamous Cell Carcinoma of the Lung. Future Oncology. 11(15). 2175–2191. 5 indexed citations
10.
Hall, Peter E., et al.. (2015). Lesson of the month 1: A rash decision. Clinical Medicine. 15(2). 206–207. 1 indexed citations
11.
Thurman, Andrea R., Thomas Kimble, Peter E. Hall, Jill L. Schwartz, & David F. Archer. (2012). Medroxyprogesterone acetate and estradiol cypionate injectable suspension (Cyclofem) monthly contraceptive injection: steady-state pharmacokinetics. Contraception. 87(6). 738–743. 13 indexed citations
12.
Hall, Peter E., Sheena Derry, R Andrew Moore, & Henry J McQuay. (2009). Single dose oral lornoxicam for acute postoperative pain in adults. Cochrane Database of Systematic Reviews. 2019(5). CD007441–CD007441. 24 indexed citations
13.
Loulier, Karine, Justin D. Lathia, Véronique Marthiens, et al.. (2009). β1 Integrin Maintains Integrity of the Embryonic Neocortical Stem Cell Niche. PLoS Biology. 7(8). e1000176–e1000176. 143 indexed citations
14.
Hall, Peter E., Justin D. Lathia, Maeve A. Caldwell, & Charles ffrench‐Constant. (2008). Laminin enhances the growth of human neural stem cells in defined culture media. BMC Neuroscience. 9(1). 71–71. 104 indexed citations
15.
Bahamondes, Luís, Juan Dı́az, Carlos Alberto Petta, & Peter E. Hall. (1998). Weight Variation in Users of the Once-a-Month Injectable Contraceptive Cyclofem. Advances in Contraception. 14(4). 185–192. 6 indexed citations
16.
Hall, Peter E.. (1998). New once‐a‐month injectable contraceptives, with particular reference to Cyclofem®/Cyclo‐ProveraTM. International Journal of Gynecology & Obstetrics. 62(S1). S43–56. 16 indexed citations
17.
18.
Hall, Peter E., et al.. (1993). Anorexia in the elderly—an annotation. International Journal of Eating Disorders. 14(4). 497–499. 22 indexed citations
19.
Hall, Peter E., et al.. (1992). Lipid and biochemical changes after low-dose oral contraception. Contraception. 46(3). 227–241. 17 indexed citations
20.
Chutivongse, Supawat, N. Crona, Göran Samsioe, et al.. (1988). A multicentre comparative study of serum lipids and lipoproteins in four groups of oral combined contraceptive users and a control group of IUD users. Contraception. 38(6). 605–629. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by P Cortinovis-Tourniaire Breakdown of academic impact, for papers by Padmalaya Das Breakdown of academic impact, for papers by Stephen R. Braddock Breakdown of academic impact, for papers by P. J. McLaughlin Breakdown of academic impact, for papers by David B. Flannery Breakdown of academic impact, for papers by Arabella Smith Breakdown of academic impact, for papers by Aurora Sánchez Breakdown of academic impact, for papers by J. Wahlström Breakdown of academic impact, for papers by Peter T. Rowley
Rankless by CCL
2026